MDxHealth Listing Prospectus 2021 English I Français
Dr. Bednarski currently serves as a Partner of MVM Partners LLP. Before joining MVM in 2008, he was a Partner at Advent Healthcare Ventures and a Principal at Advent International Corporation. Prior to Advent, he was a Director in the Corporate Finance Group of Silicon Valley Bank. Dr. Bednarski has a B.S. degree in Neural Science from Brown University and a Ph.D. in Biological Sciences from the University of California, Irvine.
Mr. Hardison was most recently the President and Chief Executive Officer, and served on the board of directors, of Biotheranostics, Inc., a molecular diagnostic company focused on oncology, from February 2017 until it was acquired by Hologic, Inc. in February 2021. From April 2010 to March 2016, Mr. Hardison was the President and Chief Executive Officer of Good Start Genetics, a molecular genetic testing and information company. For more than 20 years prior to that, Mr. Hardison held various executive and senior management positions at companies including Laboratory Corporation of America (LabCorp), Exact Sciences Corporation, Quest Diagnostics Inc., and Smith Kline Beecham Corporation. He currently serves as an independent director on the boards of directors of Stemina Biomarker Discovery, Inc., Seventh Sense Biosystems, BioPorto, Inc. and IQuity, Inc. He also formerly served on the board of directors of Exact Sciences Corporation (Nasdaq: EXAS) from May 2000, through its initial public offering in February 2001, until August 2007. Mr. Hardison received his Bachelor of Arts degree, in political science, from the University of North Carolina, Chapel Hill.
CAP Accreditation Certification
Centers for Medicare & Medicaid Services (Clinical Laboratory Improvement Amendments) Certificate of Accreditation
New York Department of Health Clinical Lab Permit (SelectMDx & ConfirmMDx)
State of California Department of Public Health Clinical Laboratory License
State of Maryland License
State of Pennsylvania License
State of Rhode Island License
Health Canada License
MDxHealth’s Nijmegen Laboratory: ISO 13485:2016 Certificate of Registration
Mr. McGarrity has more than 25 years of experience in the healthcare industry with a unique combination of device, diagnostics and biotechnology experience. Michael was most recently the CEO of Sterilis Medical. Prior to Sterilis Michael was the CEO of Nanosphere (NASDAQ: NSPH), a nanotechnology-based molecular diagnostics company, where he engineered an operational and strategic turnaround that resulted in its successful sale to Luminex (NASDAQ: LMNX) in 2016. Prior to Nanosphere, McGarrity spent 13 years at Stryker Corporation (NYSE: SYK). McGarrity served in leadership roles in sales and marketing and led Stryker into new growth markets such as post-operative pain management, surgical fluid waste management and interventional pain management. He also had executive general management responsibility for a newly created business unit focused on interventional spine pain management. Michael received a Bachelor of Arts degree from the University of Notre Dame and began his career in commercial banking.
Mr. Sollee has more than 20 years of experience in the healthcare industry, including senior management roles in both private and publicly listed pharmaceuticals, health information technology and molecular diagnostics companies. He has served as chief legal counsel to MDxHealth since its inception in 2003. Prior to MDxHealth, he led the Life Sciences Practice Group at the law firm of Kennedy Covington (now K&LGates) and held senior legal and management positions at TherapyEdge and Triangle Pharmaceuticals. In addition, he has practiced as a corporate attorney in the Washington D.C. legal firm Swidler & Berlin and as an investment banker at Smith Barney in New York. Mr. Sollee received a Juris Doctorate in Law and a Masters degree in International Law from Duke University, a BA degree from Harvard University, and has been awarded New York, Washington D.C. and North Carolina legal bar certifications.
Dr. Regine Slagmulder is a partner and full professor in management accounting & control at Vlerick Business School. Previously, she worked as a strategy practice consultant at McKinsey & Company. She also previously worked as a professor of management accounting at INSEAD and at the University of Tilburg. She serves. as an independent director and chair of the audit committee on the board of the investment company Quest for Growth. (since 2011) and of Ekopak (since 2021), both listed on Euronext. Dr. Slagmulder graduated in civil electrotechnical engineering and industrial management from the University of Ghent, after which she took a management doctorate at Vlerick Business School. As part of her research activities, she was a research fellow attached to INSEAD, Boston University (USA) and the P. Drucker Graduate Management Center at Claremont University (USA).
We are committed to making our tests accessible and affordable to your patients. MDxHealth’s Patient First Promise Program was created to assist patients throughout the billing process. We will work directly with each patient to ensure their complete satisfaction.
Jan Pensaert is the Founding Managing Partner of Valiance. He brings over 20 years of experience in growth investing. He leads the Investment Committee for the Valiance Funds and is responsible for all aspects of the Funds’ investment processes. Jan currently serves on the Board of several Valiance entities funds and portfolio companies including MDxHealth, JenaValve, MyCartis, and 4Tech. Prior to founding Valiance, Jan was CEO of La Fayette, where during his tenure the La Fayette Funds increased in AUM from $750 million to $5.5 billion. Before that, he was responsible for the Permal Group’s European-based investment management and research activities, and prior to that, he worked at Lazard in Corporate Finance M&A. Jan holds a BA in Business Economics from Gent University in Belgium, and a Masters in Banking & Finance from the University of Aix-Marseille, France.
Rudi Mariën is currently Director of Biocartis S.A. (Swirtzeland). He is also President and CEO of Gengest Bvba and Biovest CommVa.
Through his management company, Gengest BVBA, Mr. Mariën has board mandates in different stock listed (Quest For Growth, Devgen… ) and private biotech companies (ActogenixNV, Pharmaneuroboost NV, Oystershell NV…).
Previously Mr. Mariën was founder, reference shareholder and managing director of Barc NV group, a leading international centralized clinical laboratory, exclusively dedicated to pharmaceuticals studies.
He was also the co-founder, reference shareholder and chairman of the biotech company Innogenetics NV.
Koen Hoffman has served as Independent Chairman of the Board of Directors of Fagron NV since May 8, 2017. He obtained a Master in Applied Economics at the University of Ghent in 1990 and a Master in Business Administration at Vlerick Business School in Ghent in 1991. Mr. Hoffman was appointed Chief Executive Officer of Value Square in August 2016. Prior to joining Value Square, he was Chief Executive Officer of KBC Securities, member of the supervisory board of Patria Securities and member of the board of directors of Omnia Travel Belgium. He started his career at the corporate finance department of KBC Bank in 1992.
Ms. Windels is the CEO of immunodiagnostic company Antelope Dx BV and has 20 years of experience in the biotechnology sector with a track record of building and structuring organizations, fundraising, M&A, public capital markets and corporate strategies. At Biocartis, she was CEO and interim and Deputy CEO from September 2015 until September 2017 and CFO from 2011 until September 2015. Previously, Mrs. Windels worked as an independent CFO for several private biotech companies, and from 1999 to 2008 she was CFO of Devgen. Currently, Mrs. Windels serves as a board member at Erytech and Celyad. In the past, she also served on the boards of Devgen, Biocartis, Ablynx, VIB, and FlandersBio. Mrs. Windels holds a Masters in Economics (commercial engineer) from the University of Leuven, Belgium.
Schedule FedEx Pick UpView and Download SelectMDx Test Requisition Form (TRF)View and Download Urine Collection and Preparation InstructionsView and Download Specimen Requirements and Patient Eligibility
View and Download Test Request Form DE | EN | ES | FR | IT | NL | PLView and Download SelectMDx Instructions for UseView and Download UrNCollect Instructions for Use
To Order Pre-printed Test Requisition Forms:
Order Supplies OnlineCall 866.259.5644Email firstname.lastname@example.org
View and Download ConfirmMDx Test Requisition Form (TRF)View and Download ConfirmMDx Specimen Requirements and Patient Eligibility
To order ConfirmMDx Tissue Transport Kits:
Schedule FedEx Pick Up
MDxHealth directly contracts with most insurance providers to obtain the best coverage possible. MDxHealth will submit a claim to your insurance company or Medicare for the test.
Depending on your insurance, you may be responsible for copayment, coinsurance, and/or deductible amounts according to your individual plan. If you have questions about coverage, please contact our Patient Advocate Team.
Your insurance provider will send you a claim summary called an Explanation of Benefits (EOB). The EOB explains which medical services were covered by your insurance provider on your behalf. It is important to note the EOB IS NOT A BILL.
MDxHealth has self-pay options available. Please contact our Patient Advocate Team for more information.
Lieve Verplancke MD was nominated as an Independent Non-Executive Director at the Company’s Annual General shareholders Meeting held on 26 May 2017 in Diegem, Belgium. Ms. Verplancke, a Belgian national, began her career in 1984 with The Beecham Group (now part of GlaxoSmithKline), and has since held key management positions with Merck & Co., as well as Bristol-Myers Squibb, where she served as Managing Director, leading their Belgian/GDL subsidiary, until 2012. Ms. Verplancke has also served as a Board Member for Brussels-based Europe Hospitals; the Imelda Hospital in Bonheiden; and the Euronext fund, Quest for Growth and Materialise. She is also the Founder and Managing Director of Qaly@Beersel, an elderly care center in Belgium. In addition to being a medical doctor (MD – KULeuven University), Ms. Verplancke holds a postgraduate degree in Economics and an MBA from the University of Antwerp. She has also completed courses at INSEAD, CEDEP, Columbia University and the Vlerick Business School, and is a certified Executive Coach (PCC).
MDxHealth will honor test cancellation requests any time prior to the start of the analytical testing phase. Test cancellation requests must be submitted from the person authorized to cancel a test, following the instructions below:
Contact Client Services at 866-259-5644 for test cancellation.
A Test Cancellation Form will be sent to the authorized person for signature.
Return the completed and signed Test Cancellation Form by fax to MDxHealth 949-788-0014.
If the cancellation request is received after the specimen has entered in the analytical testing phase, the request cannot be honored and the usual test charge will be assessed.
View and Download ConfirmMDx Test Requisition Form
View and Download Specimen Requirements and Patient Eligibility
Contact MDxHealth Client Services:Phone: 866.259.5644Fax: 949.788.0014Email: email@example.com
Thank you! Your supply order had been submitted successfully. You will receive an email with confirmation within 24 hours.
Information, including Personal Health Information as defined in 45 CFR 160.501 (“PHI”), accessed and/or retrieved from the Site, is intended only for the review and/or use by authorized users for legitimate purposes. You may permit authorized members of your staff (your “Provider Group”) to use the Site, only under the following conditions:
By accessing the Site, you and each member of your Provider Group (each, a “User”) agrees:
Access and/or retrieval of information from the Site for any other purpose is expressly prohibited. User’s access to the Site will be recorded electronically, and Users consent to having all or any part of their use of and access to the Site recorded audited or reviewed at any time.
Each User hereby agrees to indemnify, defend, and hold harmless MDxHealth (“MDxHealth,” we,” “our” or “us“) and any parent, subsidiary or affiliated entities, and our and their respective officers, directors, employees, and agents, from and against any claim, cost or liability, including reasonable attorneys’ fees, arising out of or relating to the use of the Site by you or any person gaining access to the Site under credentials assigned to you or a member of your Provider Group. In addition, you hereby release us and any parent, subsidiary or affiliated entities, our officers and employees, and officers and employees of any parent, subsidiary or affiliated entities from any and all claims, demands, debts, obligations, damages (actual or consequential), costs, and expenses of any kind or nature whatsoever, whether known or unknown, suspected or unsuspected, disclosed or undisclosed, that you may have against them arising out of or in any way related to such disputes and/or to any services or materials available at the Site. You hereby agree to waive all laws that may limit the efficacy of such releases.
In no event shall we be liable for any direct, indirect, special, punitive, incidental or consequential damages (including, without limitation, personal injury/wrongful death, lost profits, or damages resulting from lost data or business interruption) resulting from the use or inability to use the site, whether based on warranty, contract, tort, or any other legal theory, and whether or not we have been advised of the possibility of such damages.
The site is provided “as is” and without warranties of any kind either express or implied. to the fullest extent permissible pursuant to applicable law, we disclaim all warranties, express or implied, including, but not limited to, implied warranties of merchantability, fitness for a particular purpose, title and on-infringement. we do not warrant that the functions contained in the site will be uninterrupted or error-free, that defects will be corrected, or that the site or the server(s) that makes our site available or hyperlinked site are free of viruses or other harmful components or that our site, server(s) or hyperlinked sites will be accessible at all times.
Thank you! Your request had been submitted successfully. You will receive an email with directions on how to set up your user ID and password within 24 hours.
MDxHealth understands that every situation is unique, which is why we offer personalized payment options to ensure affordability for all patients. Please contact the Patient Advocate Team to discuss your options.
Please contact the Patient Advocate Team to discuss personalized payment options:
Toll free: 866-259-7001, Monday-Friday, 6:00AM-4:30PM PT